LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
LTR Pharma has entered into an exclusive pilot commercialisation agreement with Marius Pharmaceuticals, a US pharmaceutical company focused on men’s health, to introduce Marius’ lead
LTR Pharma has executed a definitive Compounding and Supply Agreement with Strive Specialties Inc., a leading U.S. Section 503A compounding pharmacy, converting the previously announced
LTR Pharma has executed a definitive Telehealth Distribution Agreement with Shed Holdings LLC, a leading U.S. direct-to-consumer telehealth platform, converting the previously announced binding Term